Lung Cancer
Breast cancer surpasses lung as top cause of cancer death among Black women
Breast cancer has surpassed lung cancer as the leading cause of cancer-associated death among Black women in the U.S., according to an American Cancer Society report.
CAC tied to MI, stroke risk in non-small cell lung cancer treated with thoracic radiation
Discovery of coronary artery calcium in patients with non-small cell lung cancer undergoing thoracic radiation was associated with elevated risk for MI and stroke, even when found in small amounts, researchers reported.
FDA committee calls for more research into lung cancer therapy studied only in China
The FDA should not make a regulatory decision on sintilimab for advanced lung cancer until additional study demonstrates applicability to U.S. patients, an advisory committee determined.
Reporting of censoring in oncology trials lacks transparency, study shows
Cancer clinical trials supporting FDA approvals significantly differ in reporting of withdrawal of consent or loss to follow-up and early drug discontinuation for adverse events, according to study results.
USPSTF guideline revision could reduce racial disparity in lung cancer screening access
The U.S. Preventive Services Task Force’s 2021 guideline for lung cancer screening improved upon previous fixed-screening criteria and may reduce racial disparities in access, according to a study published in JAMA Oncology.
Antihistamines may impact response to immune checkpoint inhibitors for cancer
Cancer cell-derived or allergic reaction-released histamine dampened antitumor immunity and conferred resistance to cancer immunotherapy, according to a retrospective study published in Cancer Cell.
Immunotherapy benefits older patients with cancer, but closer monitoring may be warranted
Older patients with cancer benefited from single-agent immune checkpoint inhibitors but had higher rates of adverse events and therapy discontinuation with increasing age, according to results of a retrospective study in JAMA Oncology.
Sugemalimab extends OS in stage IV non-small cell lung cancer
The addition of sugemalimab to first-line chemotherapy significantly prolonged OS among patients with stage IV non-small cell lung cancer, according to topline data released by the agent’s manufacturer.
HF may be tied to cancer incidence, mortality in those 50 years and older
HF may be associated with cancer incidence as well as risk for cancer-related mortality, especially among individuals aged 50 to 70 years, according to new data published in JACC: CardioOncology.
Blood test plus risk model may help improve selection for lung cancer screening
A blood test based on a four-marker protein panel combined with an independent risk prediction model that accounts for smoking history significantly improved patient selection for lung cancer screening, according to study results.